ABEO
Abeona Therapeutics Inc.
Biotechnology
Market Cap$318M
5Y Perf.-93.0%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
ABEO vs ALNY vs IONS vs RARE
Revenue, margins, valuation, and 5-year total return — side by side.
ALNY
Alnylam Pharmaceuticals, Inc.
Biotechnology
Market Cap$39.48B
5Y Perf.+118.8%
IONS
Ionis Pharmaceuticals, Inc.
Biotechnology
Market Cap$12.56B
5Y Perf.+35.2%
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.-61.8%
ABEO vs ALNY vs IONS vs RARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ABEO | ALNY | IONS | RARE |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $318M | $39.48B | $12.56B | $2.57B |
| Revenue (TTM) | $6M | $4.29B | $1.06B | $669M |
| Net Income (TTM) | $71M | $577M | $-327M | $-609M |
| Gross Margin | 26.3% | 80.9% | 98.3% | 83.6% |
| Operating Margin | -15.4% | 17.5% | -33.3% | -83.9% |
| Forward P/E | 5.7x | 44.2x | — | — |
| Total Debt | $25M | $1.28B | $2.61B | $1.28B |
| Cash & Equiv. | $78M | $1.66B | $372M | $434M |
ABEO vs ALNY vs IONS vs RARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ABEO
ALNY
IONS
RARE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Abeona Therapeutics… (ABEO) | 100 | 7.0 | -93.0% |
| Alnylam Pharmaceuti… (ALNY) | 100 | 218.8 | +118.8% |
| Ionis Pharmaceutica… (IONS) | 100 | 135.2 | +35.2% |
| Ultragenyx Pharmace… (RARE) | 100 | 38.2 | -61.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ABEO vs ALNY vs IONS vs RARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ABEO leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Ionis Pharmaceuticals, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
ABEO
Abeona Therapeutics Inc.
The Income Pick
ABEO carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 1 yrs, beta 1.34
- 222.9% revenue growth vs RARE's 20.1%
- Better valuation composite
- 12.2% margin vs RARE's -91.0%
Best for: income & stability
ALNY
Alnylam Pharmaceuticals, Inc.
The Growth Play
ALNY is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 65.2%, EPS growth 206.9%, 3Y rev CAGR 53.0%
- 411.9% 10Y total return vs IONS's 121.1%
Best for: growth exposure and long-term compounding
IONS
Ionis Pharmaceuticals, Inc.
The Defensive Pick
IONS is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.
- Lower volatility, beta 0.55, current ratio 3.83x
- Beta 0.55, current ratio 3.83x
- Beta 0.55 vs RARE's 1.42
- +129.9% vs RARE's -21.8%
Best for: sleep-well-at-night and defensive
RARE
Ultragenyx Pharmaceutical Inc.
The Growth Angle
RARE lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ABEO | 222.9% revenue growth vs RARE's 20.1% |
| Value | ABEO | Better valuation composite |
| Quality / Margins | ABEO | 12.2% margin vs RARE's -91.0% |
| Stability / Safety | IONS | Beta 0.55 vs RARE's 1.42 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | IONS | +129.9% vs RARE's -21.8% |
| Efficiency (ROA) | ABEO | 35.8% ROA vs RARE's -45.8%, ROIC -89.8% vs -89.4% |
ABEO vs ALNY vs IONS vs RARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
FY 2025
FY 2025
ABEO vs ALNY vs IONS vs RARE — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIONSLAGGINGRARE
Who Leads Where
IONS leads in 2 of 6 categories
ALNY leads 1 • ABEO leads 0 • RARE leads 0 • 2 tied
Explore the data ↓RAREUltragenyx Pharmaceut…
0leads
ABEOAbeona Therapeutics I…
0leads
ALNYAlnylam Pharmaceutica…
1leads
IONSIonis Pharmaceuticals…
2leads
6 Total Categories
CATEGORYLEADERvs ALNYvs ABEOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ALNY4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
IONS3/6
Risk & VolatilityBeta, volatility, and downside exposure
IONS2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ALNY leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALNY is the larger business by revenue, generating $4.3B annually — 736.6x ABEO's $6M. ABEO is the more profitable business, keeping 12.2% of every revenue dollar as net income compared to RARE's -91.0%. On growth, ALNY holds the edge at +96.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ABEOAbeona Therapeuti… | ALNYAlnylam Pharmaceu… | IONSIonis Pharmaceuti… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $6M | $4.3B | $1.1B | $669M |
| EBITDAEarnings before interest/tax | -$86M | $677M | $4.5B | -$536M |
| Net IncomeAfter-tax profit | $71M | $577M | -$327M | -$609M |
| Free Cash FlowCash after capex | -$84M | $641M | -$971M | -$487M |
| Gross MarginGross profit ÷ Revenue | +26.3% | +80.9% | +98.3% | +83.6% |
| Operating MarginEBIT ÷ Revenue | -15.4% | +17.5% | -33.3% | -83.9% |
| Net MarginNet income ÷ Revenue | +12.2% | +13.5% | -30.9% | -91.0% |
| FCF MarginFCF ÷ Revenue | -14.5% | +15.0% | -91.8% | -72.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +96.4% | +87.0% | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -56.5% | +4.4% | +39.8% | -17.2% |
ALNY leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — ABEO and IONS and RARE each lead in 1 of 3 comparable metrics.
Valuation Metrics
At 5.7x trailing earnings, ABEO trades at a 96% valuation discount to ALNY's 127.0x P/E.
| Metric | ABEOAbeona Therapeuti… | ALNYAlnylam Pharmaceu… | IONSIonis Pharmaceuti… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| Market CapShares × price | $318M | $39.5B | $12.6B | $2.6B |
| Enterprise ValueMkt cap + debt − cash | $264M | $39.1B | $14.8B | $3.4B |
| Trailing P/EPrice ÷ TTM EPS | 5.71x | 127.00x | -31.94x | -4.48x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 44.18x | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 70.17x | — | — |
| Price / SalesMarket cap ÷ Revenue | 54.57x | 10.63x | 13.31x | 3.82x |
| Price / BookPrice ÷ Book value/share | 2.40x | 50.50x | 24.87x | — |
| Price / FCFMarket cap ÷ FCF | — | 84.84x | — | — |
Evenly matched — ABEO and IONS and RARE each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
Evenly matched — ABEO and ALNY each lead in 5 of 9 comparable metrics.
Profitability & Efficiency
ALNY delivers a 98.3% return on equity — every $100 of shareholder capital generates $98 in annual profit, vs $-6 for RARE. ABEO carries lower financial leverage with a 0.16x debt-to-equity ratio, signaling a more conservative balance sheet compared to IONS's 5.35x. On the Piotroski fundamental quality scale (0–9), ABEO scores 6/9 vs IONS's 3/9, reflecting solid financial health.
| Metric | ABEOAbeona Therapeuti… | ALNYAlnylam Pharmaceu… | IONSIonis Pharmaceuti… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | +53.2% | +98.3% | -58.6% | -6.1% |
| ROA (TTM)Return on assets | +35.8% | +11.8% | -10.1% | -45.8% |
| ROICReturn on invested capital | -89.8% | +33.4% | -12.8% | -89.4% |
| ROCEReturn on capital employed | -63.4% | +15.3% | -14.1% | -46.4% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.16x | 1.62x | 5.35x | — |
| Net DebtTotal debt minus cash | -$53M | -$379M | $2.2B | $842M |
| Cash & Equiv.Liquid assets | $78M | $1.7B | $372M | $434M |
| Total DebtShort + long-term debt | $25M | $1.3B | $2.6B | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | 19.23x | 2.02x | -3.64x | -14.49x |
Evenly matched — ABEO and ALNY each lead in 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
IONS leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALNY five years ago would be worth $22,537 today (with dividends reinvested), compared to $1,499 for ABEO. Over the past 12 months, IONS leads with a +129.9% total return vs RARE's -21.8%. The 3-year compound annual growth rate (CAGR) favors IONS at 29.3% vs RARE's -17.8% — a key indicator of consistent wealth creation.
| Metric | ABEOAbeona Therapeuti… | ALNYAlnylam Pharmaceu… | IONSIonis Pharmaceuti… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +8.7% | -26.1% | -4.6% | +10.7% |
| 1-Year ReturnPast 12 months | +9.5% | +7.0% | +129.9% | -21.8% |
| 3-Year ReturnCumulative with dividends | +84.3% | +40.9% | +116.1% | -44.5% |
| 5-Year ReturnCumulative with dividends | -85.0% | +125.4% | +108.0% | -77.2% |
| 10-Year ReturnCumulative with dividends | -90.7% | +411.9% | +121.1% | -59.4% |
| CAGR (3Y)Annualised 3-year return | +22.6% | +12.1% | +29.3% | -17.8% |
IONS leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
IONS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
IONS is the less volatile stock with a 0.55 beta — it tends to amplify market swings less than RARE's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IONS currently trades 87.6% from its 52-week high vs ALNY's 59.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ABEOAbeona Therapeuti… | ALNYAlnylam Pharmaceu… | IONSIonis Pharmaceuti… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.34x | 0.71x | 0.55x | 1.42x |
| 52-Week HighHighest price in past year | $7.54 | $495.55 | $86.74 | $42.37 |
| 52-Week LowLowest price in past year | $4.00 | $245.96 | $31.66 | $18.29 |
| % of 52W HighCurrent price vs 52-week peak | +76.5% | +59.7% | +87.6% | +61.7% |
| RSI (14)Momentum oscillator 0–100 | 69.4 | 43.8 | 58.8 | 66.6 |
| Avg Volume (50D)Average daily shares traded | 1.2M | 1.1M | 2.0M | 1.8M |
IONS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ABEO as "Buy", ALNY as "Buy", IONS as "Buy", RARE as "Buy". Consensus price targets imply 194.6% upside for ABEO (target: $17) vs 41.1% for IONS (target: $107).
| Metric | ABEOAbeona Therapeuti… | ALNYAlnylam Pharmaceu… | IONSIonis Pharmaceuti… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $17.00 | $445.67 | $107.27 | $51.50 |
| # AnalystsCovering analysts | 9 | 52 | 32 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | — | — | 1 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
IONS leads in 2 of 6 categories (Total Returns, Risk & Volatility). ALNY leads in 1 (Income & Cash Flow). 2 tied.
Best OverallIonis Pharmaceuticals, Inc. (IONS)Leads 2 of 6 categories
Loading custom metrics...
ABEO vs ALNY vs IONS vs RARE: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ABEO or ALNY or IONS or RARE a better buy right now?
For growth investors, Alnylam Pharmaceuticals, Inc.
(ALNY) is the stronger pick with 65. 2% revenue growth year-over-year, versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Abeona Therapeutics Inc. (ABEO) offers the better valuation at 5. 7x trailing P/E, making it the more compelling value choice. Analysts rate Abeona Therapeutics Inc. (ABEO) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ABEO or ALNY or IONS or RARE?
On trailing P/E, Abeona Therapeutics Inc.
(ABEO) is the cheapest at 5. 7x versus Alnylam Pharmaceuticals, Inc. at 127. 0x.
03Which is the better long-term investment — ABEO or ALNY or IONS or RARE?
Over the past 5 years, Alnylam Pharmaceuticals, Inc.
(ALNY) delivered a total return of +125. 4%, compared to -85. 0% for Abeona Therapeutics Inc. (ABEO). Over 10 years, the gap is even starker: ALNY returned +411. 9% versus ABEO's -90. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ABEO or ALNY or IONS or RARE?
By beta (market sensitivity over 5 years), Ionis Pharmaceuticals, Inc.
(IONS) is the lower-risk stock at 0. 55β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 160% more volatile than IONS relative to the S&P 500. On balance sheet safety, Abeona Therapeutics Inc. (ABEO) carries a lower debt/equity ratio of 16% versus 5% for Ionis Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ABEO or ALNY or IONS or RARE?
By revenue growth (latest reported year), Alnylam Pharmaceuticals, Inc.
(ALNY) is pulling ahead at 65. 2% versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Over a 3-year CAGR, ABEO leads at 60. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ABEO or ALNY or IONS or RARE?
Abeona Therapeutics Inc.
(ABEO) is the more profitable company, earning 1223% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 1223% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALNY leads at 13. 5% versus -1536. 9% for ABEO. At the gross margin level — before operating expenses — IONS leads at 98. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ABEO or ALNY or IONS or RARE more undervalued right now?
Analyst consensus price targets imply the most upside for ABEO: 194.
6% to $17. 00.
08Which pays a better dividend — ABEO or ALNY or IONS or RARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is ABEO or ALNY or IONS or RARE better for a retirement portfolio?
For long-horizon retirement investors, Alnylam Pharmaceuticals, Inc.
(ALNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 71), +411. 9% 10Y return). Both have compounded well over 10 years (ALNY: +411. 9%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ABEO and ALNY and IONS and RARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ABEO is a small-cap deep-value stock; ALNY is a mid-cap high-growth stock; IONS is a mid-cap high-growth stock; RARE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Net Margin>
%
(ABEO: 1223.1% · ALNY: 13.5%)P/E Ratio<
x
(ABEO: 5.7x · ALNY: 127.0x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.